TSXV:CLAS.H - Post by User
Post by
Red~Oneon Sep 03, 2022 6:58pm
154 Views
Post# 34940397
N.O. in the news
N.O. in the news
Beyond Air® Affiliate Beyond Cancer™ Doses Initial Patient in First-in-Human Phase 1 Study of Ultra-High Concentration Nitric Oxide Therapy at Tel Aviv Sourasky Medical Center (Ichilov)
Jedidiah Monson, M.D., Chief Medical Officer of Beyond Cancer, added, “This open-label, first-in-human, single administration, Phase I study is a promising advancement as a new approach towards treating solid tumors with nitric oxide. The study will evaluate the maximum tolerated dose (MTD), safety and immune biomarkers of UNO injection into solid tumors that are not amenable to or have failed standard treatment.”